Chester County News and Community Website
WILMINGTON, DE — AstraZeneca’s experimental cancer drug sonesitatug vedotin reduced the risk of death by 53% in patients receiving third-line or later treatment for advanced gastric and related cancers, according …
AstraZeneca Drug Cuts Death Risk in Advanced Gastric Cancer Read More
WAYNE, PA — Aclaris Therapeutics Inc. (Nasdaq: ACRS) plans to advance its experimental antibody ATI-052 into a Phase 2b trial for eosinophilic esophagitis in early 2027, concentrating development spending on …
Aclaris Prioritizes Esophageal Drug Trial After Early Results Read More WILMINGTON, DE — AstraZeneca’s TAGRISSO combined with savolitinib extended median survival by nearly five months compared with chemotherapy in a Phase III trial involving patients with EGFR-mutated non-small cell lung …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More WILMINGTON, DE — AstraZeneca’s IMFINZI combined with Amgen’s tarlatamab-dlle extended median survival to 21.1 months in patients with extensive-stage small cell lung cancer, compared with 12.7 months for IMFINZI alone, …
AstraZeneca Drug Combination Extends Lung Cancer Survival Read More
WILMINGTON, DE — Incyte Corp. (Nasdaq: INCY) and Genmab A/S (Nasdaq: GMAB) have agreed to jointly support an early-stage clinical trial combining two experimental cancer drugs with chemotherapy, expanding their …
Incyte, Genmab to Test Drug Combination for Colorectal Cancer Read More
YARDLEY, PA — Savara Inc. (Nasdaq: SVRA) reported improvements in pulmonary gas transfer and lung imaging measures among patients with a rare respiratory disease who received its experimental drug molgramostim, …
Savara Reports Molgramostim Benefits in Exploratory Lung Study Read More
WILMINGTON, DE — AstraZeneca and Amgen reported that their immunotherapy TEZSPIRE significantly reduced esophageal inflammation and swallowing difficulties in a Phase III clinical trial, strengthening the companies’ case for expanding …
AstraZeneca, Amgen Report Phase III Success for TEZSPIRE Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) reported that its Crohn’s disease treatment Tremfya sustained or improved fistula remission through 48 weeks in a Phase 3 clinical trial, …
J&J’s Tremfya Sustains Crohn’s Remission Through 48 Weeks Read More
RADNOR, PA — Mineralys Therapeutics Inc. (Nasdaq: MLYS) reported that its experimental hypertension drug lorundrostat reduced a key marker of kidney damage by 52.2% compared with placebo in patients with …
Mineralys Drug Cuts Kidney Damage Marker 52% in Trial Read More
NEW HOPE, PA — Orchestra BioMed Holdings Inc. (Nasdaq: OBIO) will outline clinical development plans and upcoming trial milestones for two cardiovascular technologies at a November 12 investor event in …
Orchestra BioMed to Detail Pivotal Heart Device Trials Read More